Biogen’s no good week; Inside gene editing's open secret; Novo Nordisk absorbs RNAi partner; Boosters for all; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
We are wrapping up this year’s special report on 20 trailblazing women in biopharma R&D, and can’t be more excited to share their stories on December 7, both through the written profiles and a live event, followed by a panel on gender issues moderated by Nicole DeFeudis and myself. Learn more and sign up here.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.